Day One

• Advancing the CagriSema portfolio (Semaglutide + Cagrilintide) to match bariatric outcomes, utilizing dual-pathway synergy between incretin and amylin receptors to drive deeper body weight reduction while specifically preserving physical vitality and metabolic rate
• Benchmarking REDEFINE clinical data against current “gold standard” dual-agonists to prove superior 68-week weight stability, providing the robust longitudinal data required for universal global payer support and expanded cardiovascular indication labeling
• Standardizing lean-mass-to-fat-mass ratios as a core regulatory endpoint in multi-targeted trials, ensuring that “maximum weight loss” translates into high-quality metabolic health and functional physical independence for aging populations

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in obesity and weight loss drug development. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development.  

• Implementing differentiated clinical monitoring frameworks that prioritize the preservation of lean muscle mass in geriatric cohorts and the protection of linear growth trajectories in pediatric patients to ensure long-term metabolic stability
• Utilizing granular, age-stratified dosing escalations that account for the divergent pharmacokinetic profiles of adolescent developmental plasticity versus geriatric renal and hepatic decline, minimizing gastrointestinal and systemic toxicity
• Leveraging remote physiological tracking and “High-Touch” multidisciplinary protocols to proactively manage the unique psychosocial and physical vulnerabilities of extreme age groups, ensuring treatment adherence without escalating patient fatigue

• Adding oral selective androgen receptor modulators to standard incretin regimens to protect lean skeletal muscle mass during rapid weight loss, preventing the increased fall risk and frailty often seen in elderly patients on GLP-1s
• Utilizing advanced DEXA-based body composition analysis to prioritize “quality of weight loss” over simple BMI reduction, ensuring that weight loss translates into improved physical function and independence for the over-65 population
• Optimizing dual-therapy titration protocols to balance the appetite-suppressing effects of GLP-1s with the anabolic support of SARMs, delivering a comprehensive solution for geriatric obesity that satisfies both clinical and quality-of-life endpoints

• Standardizing tissue-specific permeability and “molecular-reach” as a core regulatory endpoint to move beyond systemic bioavailability as the “gold standard” for pediatric and geriatric success, leading to a more nuanced and accurate reflection of metabolic health across all ages
• Evaluating the ethics and logistics of long-term “follow-on” studies to track the 10-year impact of incretins on muscle progenitor cell health and mitochondrial function, building the robust safety database required for universal pediatric approval
• Integrating objective metabolic-reserve metrics regarding “muscular-force” and “mitochondrial-efficiency” to capture the human impact of treatment, ensuring that drug development remains focused on functional longevity rather than just cosmetic weight loss 

• Comparing semaglutide and bimagrumab, alone or in combination, during 72 weeks treatment and 32 weeks withdrawal to understand actual changes in fat and lean mass by serial DXA measurements
• Quantifying differential effects on visceral fat, subcutaneous fat, and skeletal muscle of incretins and activin pathway inhibitors • Implications for durable vs pharmacologic effects on adipose, muscle, and other tissues and the long-term cardio-metabolic consequences
• Incorporating follow-on studies to track the durability of benefits associated with various weight loss mechanisms and treatment strategies.

• Harnessing the SCAP/Insig1 pathway to downregulate SREBP-mediated lipogenesis, providing a direct physiological brake on fat accumulation that remains effective even after the intensive weight-loss phase of GLP-1 therapy is complete
• Utilizing miR-146a upregulation to mitigate hypothalamic senescence and systemic inflammation, restoring metabolic “resilience” and protecting against the weight-gain “rebound” triggered by standard hormonal therapies
• Implementing a low-dose, small molecule regimen that achieves a 55% reduction in visceral fat accumulation, offering an orally-deliverable maintenance solution that secures long-term cardiometabolic health and provides a clear value proposition for global payers

• Introduction to the Modular Next Gen Hyper15™ Delivery Platform, the first technology capable of bypassing the endosome to successfully deliver dual siRNA payloads directly to adipose tissue. This breakthrough enables precise genetic silencing within the fat cell itself, treating the tissue as a metabolic organ rather than just a storage depot.

Differentiating CCT-217 from standard-of-care incretins by moving “Beyond Appetite.” We present data showing how silencing adipose-specific genes at their mitochondrial receptors unlocks thermogenic energy expenditure and lipolysis, driving weight loss through metabolic upregulation rather than caloric restriction/starvation physiology.

A deep dive into the compositional and commercial advantage of CCT-217. We demonstrate how CCT-217 delivers Selective Fat Mass reduction and Muscle Enhancement—avoiding the sarcopenic trap of GLP-1s—while offering an Ultra-Long Duration dosing profile (6+ months) that redefines treatment adherence

Showcase your groundbreaking research and connect with peers in a vibrant, collaborative environment. Presenting at the poster session is your chance to gain visibility and engage directly with leading experts and innovators in the obesity drug development field. This is a unique opportunity to build new relationships and strengthen existing ones. Share your latest findings, gain valuable feedback, and explore potential collaborations that will shape the next generation of obesity and weight loss drugs.

To submit a poster, please contact info@hansonwade.com

• Utilizing the xRNA™ platform and “combinatorial genetics” to identify and silence high-impact metabolic targets, providing a “once-to-twice-a-year” dosing convenience that eliminates the daily or weekly “jab fatigue” associated with current peptide therapies
• Matching the durability of genetic interventions with a programmable siRNA design to offer a potent maintenance alternative, potentially capturing a dominant share of the post-incretin “transition market” by 2030 as payers demand therapies that prevent the $100B+ biological “rebound effect”
• Optimizing the metabolic “hand-off” protocol by transitioning patients from acute GLP-1 induction to RNA-based physiological regulation, ensuring permanent appetite control and improved insulin sensitivity without the “peaks and troughs” or gastrointestinal side effects of chronic hormonal supplementation

• Engineering next-generation dry-powder (DPI) and soft-mist (SMI) inhalation platforms to leverage the lung’s massive vascular surface area, bypassing the gastric proteolytic barrier entirely
• Utilizing proprietary formulation technologies to deliver therapeutic peptide concentrations that achieve rapid systemic absorption, rivaling the pharmacokinetics of subcutaneous injectables without the need for needles
• Optimizing high-volume, state-of-the-art manufacturing processes (139,000 sq. ft. capacity) to bypass global constraints of “cold-chain” distribution and specialized injection hardware, ensuring global scalability